ApoE genotype accounts for the vast majority of AD risk and AD pathology

被引:442
作者
Raber, J
Huang, YD
Ashford, JW
机构
[1] Oregon Hlth & Sci Univ, ONPRC, Div Neurosci, Dept Behav Neurosci, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, ONPRC, Div Neurosci, Dept Neurol, Portland, OR 97201 USA
[3] Univ Calif San Francisco, Dept Pathol, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA
[4] VA Med Ctr, Stanford VA Alzheimers Ctr, Palo Alto, CA USA
关键词
ApoE genotype; AD risk; AD pathology;
D O I
10.1016/j.neurobiolaging.2003.12.023
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
In this review, evidence is provided that apolipoprotein E (apoE) genotype accounts for the majority of Alzheimer's disease (AD) risk and pathology. The three major human isoforms, apoE2, apoE3, and apoE4, are encoded by different alleles (epsilon2, epsilon3, epsilon4) and regulate lipid metabolism and redistribution. ApoE isoforms differ in their effects on AD risk and pathology. Clinical and epidemiological data have indicated that the epsilon4 allele may account for 50% of AD in the United States. Further, the rarity of AD among carriers of the epsilon2 allele suggests that allelic variations in the gene encoding this protein may account for over 95% of AD cases. ApoE4 disrupts memory function in rodents. Further studies have indicated that fragments of apoE may contribute to both plaque and tangle formation. Thus, the epidemiologic and basic science evidence suggest that apoE genotype accounts for the vast majority of AD risk and pathology. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:641 / 650
页数:10
相关论文
共 64 条
[1]   Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization [J].
Arendt, T .
NEUROSCIENCE, 2001, 102 (04) :723-765
[2]   Non-familial Alzheimer's disease is mainly due to genetic factors [J].
Ashford, J. Wesson ;
Mortimer, James A. .
JOURNAL OF ALZHEIMERS DISEASE, 2002, 4 (03) :169-177
[3]  
Ashford JW, 1998, ADV DIAGNOSIS TREATM
[4]   Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease [J].
Bales, KR ;
Verina, T ;
Cummins, DJ ;
Du, YS ;
Dodel, TC ;
Saura, J ;
Fishman, CE ;
DeLong, CA ;
Piccardo, P ;
Petegnief, V ;
Ghetti, B ;
Paul, SM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15233-15238
[5]   Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition [J].
Bales, KR ;
Verina, T ;
Dodel, RC ;
Du, YS ;
Altstiel, L ;
Bender, M ;
Hyslop, P ;
Johnstone, EM ;
Little, SP ;
Cummins, DJ ;
Piccardo, P ;
Ghetti, B ;
Paul, SM .
NATURE GENETICS, 1997, 17 (03) :263-264
[6]  
Buttini M, 2002, J NEUROSCI, V22, P10539
[7]   Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation [J].
Cho, HS ;
Hyman, BT ;
Greenberg, SM ;
Rebeck, GW .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (04) :342-349
[8]   GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].
CORDER, EH ;
SAUNDERS, AM ;
STRITTMATTER, WJ ;
SCHMECHEL, DE ;
GASKELL, PC ;
SMALL, GW ;
ROSES, AD ;
HAINES, JL ;
PERICAKVANCE, MA .
SCIENCE, 1993, 261 (5123) :921-923
[9]  
CORDER EH, 1995, JAMA-J AM MED ASSOC, V273, P373, DOI 10.1001/jama.273.5.373
[10]   APOLIPOPROTEIN E-4 GENE DOSE IN CLINICALLY DIAGNOSED ALZHEIMERS-DISEASE - PREVALENCE, PLASMA-CHOLESTEROL LEVELS AND CEREBROVASCULAR CHANGE [J].
CZECH, C ;
FORSTL, H ;
HENTSCHEL, F ;
MONNING, U ;
BESTHORN, C ;
GEIGERKABISCH, C ;
SATTEL, H ;
MASTERS, C ;
BEYREUTHER, K .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1994, 243 (05) :291-292